Study study type PathologyT1T0Patientssample sizesROB Results deaths (OS) Eprogression or deaths (PFS) ERFS/DFS E

la/mBC - HR-positive - 1st line (L1) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 1st line (L1)

versus exemestane plus ridaforolimus
dalotuzumab plus ridaforolimus plus exemestane
MK-8669-064, 2017
  NCT01605396
RCTla/mBC - HR-positive - 1st line (L1)dalotuzumab plus ridaforolimus plus exemestaneridaforolimus plus exemestanePatients with metastatic or locally advanced ER-positive and HER2-negative BC40 / 40some concern
inconclusive 18%

la/mBC - HR-positive - 2nd line (L2) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2)

versus endocrine therapy
ganitumab plus endocrine therapy
QUILT-2.015, 2013
  NCT00626106
RCTla/mBC - HR-positive - 2nd line (L2)ganitumumab plus exemestane or fulvetrantplacebo plus exemestane or fulvestrantpostmenopausal women with histologically confirmed HR positive breast cancer and locally advanced or metastatic disease that could not be cured by surgery or radiation. patients from outpatient clinics and hospitals. All patients had HR-positive disease-/-low
inconclusive 78% 17%